HomepageRDY • NYSE
add
Dr Reddy's Laboratories Ltd
$Â 14,44
Na sluitingstijd:(0,90%)+0,13
$Â 14,57
Gesloten: 16 mei, 16:36:01 GMT-4 · USD · NYSE · Disclaimer
Vorige slotkoers
$Â 14,39
Dag-range
$Â 14,27 - $Â 14,46
Jaar-range
$Â 12,26 - $Â 16,89
Beurswaarde
12,09Â mld. USD
Gem. volume
2,43Â mln.
In het nieuws
Financiële informatie
Resultatenrekening
Opbrengst
Netto inkomsten
(INR) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Opbrengst | 85,06Â mld. | 20,09% |
Bedrijfskosten | 30,40Â mld. | 13,94% |
Netto inkomsten | 15,94Â mld. | 21,95% |
Netto winstmarge | 18,74 | 1,57% |
Winst per aandeel | 19,84 | 27,69% |
EBITDA | 21,42Â mld. | 23,29% |
Effectief belastingtarief | 20,85% | — |
Balans
Totale activa
Totale passiva
(INR) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Contanten en kortetermijnbeleggingen | 57,91Â mld. | -28,92% |
Totale activa | 492,99Â mld. | 27,22% |
Totale passiva | 155,82Â mld. | 45,67% |
Totaal aandelenvermogen | 337,17 mld. | — |
Uitstaande aandelen | 833,19 mln. | — |
Koers-boekwaardeverhouding | 0,04 | — |
Rendement op activa | 8,66% | — |
Rendement op kapitaal | 11,14% | — |
Kasstroom
Nettomutatie in liquide middelen
(INR) | mrt 2025info | Wijziging j-o-j |
---|---|---|
Netto inkomsten | 15,94Â mld. | 21,95% |
Operationele kasstroom | 22,00Â mld. | 90,94% |
Kasstroom uit beleggingen | -6,24Â mld. | 44,99% |
Kasstroom uit financiering | -14,43Â mld. | -2.606,57% |
Nettomutatie in liquide middelen | 1,56Â mld. | 464,72% |
Vrije kasstroom | 7,69Â mld. | -3,61% |
Over
Dr. Reddy's Laboratories Ltd. is an Indian multinational pharmaceutical company based in Hyderabad. The company was founded by Kallam Anji Reddy, who previously worked in the mentor institute Indian Drugs and Pharmaceuticals Limited. Dr. Reddy manufactures and markets a wide range of pharmaceuticals in India and overseas. The company produces over 190 medications, 60 active pharmaceutical ingredients for drug manufacture, diagnostic kits, critical care, and biotechnology.
Dr. Reddy's began as a supplier to Indian drug manufacturers, but it soon started exporting to other less-regulated markets that had the advantage of not having to spend time and money on a manufacturing plant that would gain approval from a drug licensing body such as the U.S. Food and Drug Administration. By the early 1990s, the expanded scale and profitability from these unregulated markets enabled the company to begin focusing on getting approval from drug regulators for their formulations and bulk drug manufacturing plants – in more-developed economies. This allowed their movement into regulated markets such as the US and Europe.
By 2007, Dr. Wikipedia
CEO
Opgericht
1984
Hoofdvestiging
Website
Werknemers
27.048